4.4 Review

Androgen receptor mutations for precision medicine in prostate cancer

期刊

ENDOCRINE-RELATED CANCER
卷 29, 期 10, 页码 R143-R155

出版社

BIOSCIENTIFICA LTD
DOI: 10.1530/ERC-22-0140

关键词

abiraterone; androgen receptor; antiandrogen; mutation; steroid

资金

  1. Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT), Japan [21K09347]

向作者/读者索取更多资源

Hormonal therapies are commonly used to treat advanced prostate cancer, but treatment resistance often occurs. This review summarizes the clinical landscape of AR mutations in prostate cancer and discusses their potential implications for clinical practice.
Hormonal therapies including androgen deprivation therapy and androgen receptor (AR) pathway inhibitors such as abiraterone and enzalutamide have been widely used to treat advanced prostate cancer. However, treatment resistance emerges after hormonal manipulation in most prostate cancers, and it is attributable to a number of mechanisms, including AR amplification and overexpression, AR mutations, the expression of constitutively active AR variants, intra-tumor androgen synthesis, and promiscuous AR activation by other factors. Although various AR mutations have been reported in prostate cancer, specific AR mutations (L702H, W742L/C, H87SY, F877L, and T878A/S) were frequently identified after treatment resistance emerged. Intriguingly, these hot spot mutations were also revealed to change the binding affinity of ligands including steroids and antiandrogens and potentially result in altered responses to AR pathway inhibitors. Currently, precision medicine utilizing genetic and genomic data to choose suitable treatment for the patient is becoming to play an increasingly important role in clinical practice for prostate cancer management. Since clinical data between AR mutations and the efficacy of AR pathway inhibitors are accumulating, monitoring the AR mutation status is a promising approach for providing precision medicine in prostate cancer, which would be implemented through the development of clinically available testing modalities for AR mutations using liquid biopsy. However, there are few reviews on clinical significance of AR hot spot mutations in prostate cancer. Then, this review summarized the clinical landscape of AR mutations and discussed their potential implication for clinical utilization.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据